About: Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants
Creator	Agostinelli, F Andreani, M Angelucci, E Baronciani, D De Biagi, M Donati, M Erer, B Galimberti, M Gaziev, D Giardini, C Lucarelli, G Nesci, S Polchi, P Sodani, P Talevi, N
Source	PMC
abstract	Twenty-nine patients with thalassemia and a median age of 6 years (range 1.1–33 years) were given a BMT from an alternative donor. Six of the 29 donors were HLA-phenotypically identical and two were mismatched relatives, 13 were mismatched siblings and eight were mismatched parents. Six patients received no antigen (relatives), 15 patients one antigen, five patients two antigen and three patients three antigen disparate grafts. Twenty-three patients were in class 2 or class 3, whereas six patients were in class 1. Thirteen patients were given BUCY, nine patients BUCY plus ALG, six patients BUCY plus TBI or TLI and one patient BUCY with prior cytoreductive-immunosuppressive treatment as conditioning. As GVHD prophylaxis four patients received MTX, 22 CsA + MTX + methylprednisolone (MP) and three patients CsA + MP. Thirteen of 29 patients (44.8%) had sustained engraftment. The probability of graft failure or rejection was 55%. There were no significant differences between antigen disparities and graft failure. The incidence of grade II–IV acute GVHD was 47.3% and chronic GVHD was 37.5%. The incidence of acute GVHD was higher in patients receiving one or two antigen disparate in the GVHD direction grafts (vs no antigen) (P EQ 0.04; odds ratio 10.8; 95% CI 1.5–115). The probability of overall and event-free survival was 65% and 21%, respectively, with median follow-up of 7.5 years (range 0.6–17 years) for surviving patients. The degree of HLA disparity between patient and donor did not have a significant effect on survival. The incidence of nonhematologic toxicity was low. Transplant-related mortality was 34%. GVHD (acute or chronic) was a major contributing cause of death (50%) followed by infections (30%). We conclude that at present, due to high graft failure and GVHD rates, BMT from alternative donors should be restricted to patients who have poor life expectancies because they cannot receive adequate conventional treatment or because of alloimmunization to minor blood antigens. Bone Marrow Transplantation (2000) 25, 815–821.
has issue date	2000-04-03(xsd:dateTime)
bibo:doi	10.1038/sj.bmt.1702242
bibo:pmid	10808201
has license	no-cc
sha1sum (hex)	2afcb25964dffecced16487185ae91e00c1e75ed
schema:url	https://doi.org/10.1038/sj.bmt.1702242
resource representing a document's title	Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants
has PubMed Central identifier	PMC7102364
has PubMed identifier	10808201
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:2afcb25964dffecced16487185ae91e00c1e75ed#body_text
is schema:about of	named entity 'restricted' named entity 'acute' named entity 'median age' named entity 'probability' named entity 'degree' named entity 'sustained' named entity 'GVHD' named entity 'graft' named entity 'Six' named entity 'TBI' named entity 'patients' named entity 'thalassemia' named entity 'HAVE' named entity 'CONDITIONING' named entity 'LOW' named entity 'patient' named entity 'odds ratio' named entity 'alternative' named entity 'GVHD' named entity 'The' named entity 'high' named entity 'siblings' named entity 'GVHD' named entity 'incidence' named entity 'survival' named entity '95% CI' named entity 'toxicity' named entity 'acute' named entity 'donors' named entity 'patients' named entity 'relatives' named entity 'life expectancies' named entity 'alternative' named entity 'antigen' named entity 'cytoreductive' named entity 'antigen' named entity 'MTX' named entity 'GVHD' named entity 'GVHD' named entity 'HLA' named entity 'GVHD' named entity '7.5' named entity 'Bone Marrow Transplantation' named entity '10.8' named entity 'odds ratio' named entity 'HLA' named entity 'Twenty-nine' named entity 'thalassemia' named entity 'conventional treatment' named entity 'locus' named entity 'CsA' named entity 'regression analysis' named entity 'GVHD' named entity 'globin' named entity 'aGVHD' named entity 'acyclovir' named entity 'platelet count' named entity 'bone marrow' named entity 'GVHD' named entity 'conditioning regimens' named entity 'Conventional treatment' named entity 'BMT' named entity '21%' named entity 'HLA' named entity 'BMT' named entity 'thalassemia' named entity 'HLA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software